2023-10-24 16:56:53
In patients with moderate to severe hidradenitis suppurativa (Hs), new data highlight high levels of clinically significant response with bimekizumab, a monoclonal antibody designed to selectively inhibit both interleukin 17A (Il-17A) and interleukin 17F (Il- 17F), two ‘key’ cytokines underlying inflammatory processes. These, in summary, are the results of the first analyzes of the aggregate data of two Phase 3 studies (Be Heard I and II) presented by UCB, a multinational biopharmaceutical company, during three oral presentations and several posters at the Congress of the European Academy of dermatology and venereology (Eadv) 2023 which recently took place in Berlin, Germany.
“Patients suffering from hidradenitis suppurativa – states Emmanuel Caeymaex, Executive Vice President, Immunology Solutions and Head of UCB, USA – live with one of the most complex and burdensome systemic chronic dermatological diseases. There is an urgent need for new therapeutic options capable of offer a high and durable clinical response. The data presented at Eadv demonstrated that over 48 weeks many patients treated with bimekizumab achieved high levels of response. These results suggest that inhibition of IL-17F in addition to ‘IL-17A represents a promising therapeutic approach’ for the disease.
“The Phase 3 clinical trial program on bimekizumab in hidradenitis suppurativa – explains Christos C. Zouboulis, President of the European Hs Foundation, Director of Dermatology, Venereology, Allergology and Immunology Städtisches Klinikum Dessau, and Founding Professor of Dermatology and Venereology at Brandenburg Medical School – included the most severe clinical outcomes measured by the Hiscr75-90-100 standard, in addition to the Hiscr50 standard. In these studies – he continues – bimekizumab demonstrated, at week 16, clinically significant improvements, compared to placebo, even more evident in patients who remained in the studies through week 48. Additionally, over time, improvements in disease severity were observed in the majority of patients with severe hidradenitis suppurativa at baseline who progressed to mild or moderate disease, according to the Ihs4 dynamic classification system”.
Hidradenitis suppurativa (Hs) is a chronic, recurrent, painful and debilitating inflammatory skin disease associated with systemic manifestations. The main symptoms are nodules, abscesses and fistulas, which are typically found in the armpits, groin and buttocks. People with Hs experience flare-ups of the disease and severe pain, which can have a very negative impact on their quality of life. The disease most commonly develops in early adulthood and affects approximately 1% of the population. Pain, discharge and scarring are not only a physical problem, but also cause a problem of social stigma which can lead to embarrassment, social isolation, low self-esteem, compromised sexual life impacting all aspects of life, including interpersonal relationships, education and work. The safety and efficacy of bimekizumab in this disease have not yet been established and its use is not approved by any regulatory authority worldwide.
#Ucb #good #monoclonal #results #hidradenitis #suppurativa